| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00401-013-1141-6 |
| P698 | PubMed publication ID | 23764841 |
| P2093 | author name string | V Peter Collins | |
| Yoshitaka Narita | |||
| Akihiko Yoshida | |||
| Makoto Ohno | |||
| Koichi Ichimura | |||
| Kensuke Tateishi | |||
| Nobutaka Kawahara | |||
| Shintaro Fukushima | |||
| Soichiro Shibui | |||
| Yuko Matsushita | |||
| Hideyuki Arita | |||
| Yasuji Miyakita | |||
| P2860 | cites work | An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA | Q24336971 |
| Comprehensive genomic characterization defines human glioblastoma genes and core pathways | Q24656128 | ||
| The 2007 WHO classification of tumours of the central nervous system | Q24685772 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Mutations in CIC and FUBP1 contribute to human oligodendroglioma | Q28244895 | ||
| Highly recurrent TERT promoter mutations in human melanoma | Q29614798 | ||
| TERT promoter mutations in familial and sporadic melanoma | Q29614920 | ||
| Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma | Q29616862 | ||
| High-resolution array-based comparative genomic hybridization of medulloblastomas and supratentorial primitive neuroectodermal tumors. | Q33629786 | ||
| Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma | Q34308674 | ||
| Telomerase and tumorigenesis | Q35131774 | ||
| Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes | Q35235698 | ||
| Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas | Q36236484 | ||
| Telomerase activity in 144 brain tumours | Q36292041 | ||
| Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age. | Q36713512 | ||
| TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal | Q36762656 | ||
| Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas. | Q37307623 | ||
| Molecular pathogenesis of IDH mutations in gliomas. | Q37991531 | ||
| Novel anticancer therapeutics targeting telomerase | Q38030204 | ||
| Alternative lengthening of telomeres: remodeling the telomere architecture | Q38083475 | ||
| Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers | Q40008535 | ||
| Real-time quantitative polymerase chain reaction (qPCR) analysis with fluorescence resonance energy transfer (FRET) probes reveals differential expression of the four ERBB4 juxtamembrane region variants between medulloblastoma and pilocytic astrocyt | Q41814700 | ||
| IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas | Q42164790 | ||
| Prediction of clinical course of diffusely infiltrating astrocytomas from telomerase expression and quantitated activity level | Q43806353 | ||
| Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations | Q44269667 | ||
| CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas | Q45182713 | ||
| Telomerase activity in human gliomas. | Q48469177 | ||
| MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations. | Q48824616 | ||
| Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. | Q55472960 | ||
| Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts. | Q55476495 | ||
| Telomerase activity in human brain tumours. | Q55480252 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 267-276 | |
| P577 | publication date | 2013-06-14 | |
| P1433 | published in | Acta Neuropathologica | Q343168 |
| P1476 | title | Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss | |
| P478 | volume | 126 |
| Q37160414 | A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas |
| Q33757037 | ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples samples |
| Q89762447 | Adjunctive markers for classification and diagnosis of central nervous system tumors: results of a multi-center neuropathological survey in Korea |
| Q38931930 | Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. |
| Q38777058 | Advances in the molecular genetics of gliomas - implications for classification and therapy |
| Q92786863 | Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation |
| Q38456018 | Anaplastic glioma: current treatment and management |
| Q38528700 | Applicable advances in the molecular pathology of glioblastoma |
| Q35024672 | Association of candidate single nucleotide polymorphisms with somatic mutation of the epidermal growth factor receptor pathway |
| Q47304287 | Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastomas |
| Q26738705 | Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications |
| Q112724548 | Cancer-specific loss of TERT activation sensitizes glioblastoma to DNA damage |
| Q38874534 | Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. |
| Q90749066 | Characteristics and outcomes of elderly patients with diffuse gliomas: a multi-institutional cohort study by Kansai Molecular Diagnosis Network for CNS Tumors |
| Q39937053 | Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas |
| Q38995540 | Classification of adult diffuse gliomas by molecular markers-a short review with historical footnote |
| Q41728649 | Classification of gliomas. Current progress and perspectives |
| Q35901458 | Clinical Characteristics and Prognostic Significance of TERT Promoter Mutations in Cancer: A Cohort Study and a Meta-Analysis |
| Q55021849 | Clinical and immunological correlates of long term survival in glioblastoma. |
| Q36356194 | Combination genetic signature stratifies lower-grade gliomas better than histological grade |
| Q48677433 | Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma |
| Q49317056 | Current therapeutic approaches to diffuse grade II and III gliomas. |
| Q57787252 | DNA hypermethylation within TERT promoter upregulates TERT expression in cancer |
| Q55460981 | Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas. |
| Q47720066 | Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting |
| Q38480437 | Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers |
| Q91385901 | Disruption of the β1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner |
| Q38602693 | Distinct molecular profile of diffuse cerebellar gliomas. |
| Q48915503 | Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system |
| Q47745817 | Dual-Genotype Diffuse Low-Grade Glioma: Is It Really Time to Abandon Oligoastrocytoma As a Distinct Entity? |
| Q44200074 | EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. |
| Q52564490 | Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody. |
| Q38825589 | Elucidating the cancer-specific genetic alteration spectrum of glioblastoma derived cell lines from whole exome and RNA sequencing |
| Q92107306 | Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts |
| Q38734366 | Evolving Molecular Genetics of Glioblastoma |
| Q33917659 | Expression level of hTERT is regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma |
| Q52148344 | Genetic Alterations in Gliosarcoma and Giant Cell Glioblastoma. |
| Q47579926 | Glioblastoma in neurofibromatosis 1 patients without IDH1, BRAF V600E, and TERT promoter mutations |
| Q47957409 | Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome |
| Q38787584 | High incidence of TERT mutation in brain tumor cell lines. |
| Q48857394 | High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression |
| Q40603254 | Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy. |
| Q47118202 | Human glioma stem-like cells induce malignant transformation of bone marrow mesenchymal stem cells by activating TERT expression |
| Q48015833 | IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas. |
| Q60955487 | IDH mutations but not TERTp mutations are associated with seizures in lower-grade gliomas |
| Q48663479 | IDH1 Mutation and World Health Organization 2016 Diagnostic Criteria for Adult Diffuse Gliomas: Advances in Surgical Strategy. |
| Q38227739 | IDH1/2 mutation detection in gliomas |
| Q41756350 | Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas |
| Q30381936 | Incidental diffuse low-grade gliomas: from early detection to preventive neuro-oncological surgery. |
| Q30457044 | Inhibition of telomerase recruitment and cancer cell death |
| Q38235572 | Isocitrate dehydrogenase 1 and 2 mutations in gliomas. |
| Q91839927 | Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas |
| Q91847905 | Longer genotypically-estimated leukocyte telomere length is associated with increased meningioma risk |
| Q41318930 | Malignant transformation of diffuse astrocytoma to glioblastoma associated with newly developed BRAF V600E mutation. |
| Q89044023 | Medulloblastoma in Older Adults: A Case Report and Literature Review |
| Q47292856 | Modified rapid immunohistochemical staining for intraoperative diagnosis of malignant brain tumors |
| Q28383205 | Molecular Markers in Low-Grade Glioma-Toward Tumor Reclassification |
| Q33729693 | Molecular Testing of Brain Tumor |
| Q38627095 | Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1. |
| Q92264924 | Molecular pathology of tumors of the central nervous system |
| Q38539422 | Molecular profiling of gliomas: potential therapeutic implications. |
| Q41107185 | Mutational landscape and clonal architecture in grade II and III gliomas |
| Q33688915 | Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas |
| Q37662100 | Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic |
| Q58550783 | Not the same thing: metastatic PTCs have a different background than ATCs |
| Q27002448 | Oligodendroglioma: pathology, molecular mechanisms and markers |
| Q37729676 | Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge |
| Q47861348 | Paradoxical prognostic impact of TERT promoter mutations in gliomas depends on different histological and genetic backgrounds. |
| Q38368235 | Pathology and genetics of diffuse gliomas in adults |
| Q89666640 | Practice of the New Integrated Molecular Diagnostics in Gliomas: Experiences and New Findings in a Single Chinese Center |
| Q92335530 | Prediction of IDH and TERT promoter mutations in low-grade glioma from magnetic resonance images using a convolutional neural network |
| Q89947859 | Prediction of Molecular Mutations in Diffuse Low-Grade Gliomas using MR Imaging Features |
| Q49803880 | Presence of TERT Promoter Mutations is a Secondary Event and Associates with Elongated Telomere Length in Myxoid Liposarcomas |
| Q48145997 | Preservation of Motor Function After Resection of Lower-Grade Glioma at the Precentral Gyrus and Prediction by Presurgical Functional Magnetic Resonance Imaging and Magnetoencephalography |
| Q38203283 | Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment |
| Q36107360 | Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis |
| Q93046820 | Prognostic significance of hTERT (human telomerase reverse transcriptase) promoter region mutations C228T and C250T for overall survival in spinal chordomas |
| Q42746699 | Promoting a new brain tumor mutation: TERT promoter mutations in CNS tumors |
| Q90598398 | Radiomics and MGMT promoter methylation for prognostication of newly diagnosed glioblastoma |
| Q52143329 | Radiotherapy plus concomitant temozolomide in primary gliosarcoma. |
| Q35743608 | Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. |
| Q48650546 | Revisiting TP53 Mutations and Immunohistochemistry--A Comparative Study in 157 Diffuse Gliomas |
| Q90836884 | Role of a Promoter Mutation in TERT in Malignant Transformation of Pleomorphic Xanthoastrocytoma |
| Q54256038 | Role of microRNAs Located on Chromosome Arm 10q in Malignant Gliomas. |
| Q59793008 | Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors |
| Q38260977 | Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas. |
| Q48560043 | Stereotactic biopsy: an established procedure, but still modern? The importance of brain biopsies procedures |
| Q35038477 | Surgically treated incidentally discovered low-grade gliomas are mostly IDH mutated and 1p19q co-deleted with favorable prognosis |
| Q55022358 | TERT Genetic Mutations as Prognostic Marker in Glioma. |
| Q33414576 | TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities |
| Q47339267 | TERT promoter hotspot mutations in breast cancer. |
| Q58614432 | TERT promoter methylation is significantly associated with TERT upregulation and disease progression in pituitary adenomas |
| Q54347306 | TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA. |
| Q88886558 | TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas |
| Q36962382 | TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas |
| Q28390726 | TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma |
| Q52145873 | TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas. |
| Q35833084 | TERT promoter mutations and telomere length in adult malignant gliomas and recurrences. |
| Q90238429 | TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma |
| Q37316068 | TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma |
| Q36413047 | TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas. |
| Q39150267 | TERT promoter mutations contribute to subset prognostication of lower-grade gliomas |
| Q34499685 | TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations |
| Q27852506 | TERT promoter mutations in primary and secondary glioblastomas. |
| Q33688439 | TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas |
| Q43801346 | TERT promoter mutations rather than methylation are the main mechanism for TERT upregulation in adult gliomas |
| Q28397245 | TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas |
| Q37687470 | TERT rs2853676 polymorphisms correlate with glioma prognosis in Chinese population |
| Q98386412 | Telomerase inhibition decreases esophageal squamous carcinoma cell migration and invasion |
| Q38232447 | Telomerase promoter mutations in cancer: an emerging molecular biomarker? |
| Q40199208 | Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change |
| Q26786613 | Telomerase reverse transcriptase moonlights: Therapeutic targets beyond telomerase |
| Q47266315 | Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in Middle Eastern papillary thyroid cancer. |
| Q46754264 | Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients |
| Q91028354 | Telomerase reverse transcriptase promoter mutations in cancers derived from multiple organ sites among middle eastern population |
| Q54374929 | Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma. |
| Q33830798 | Telomerase variant A279T induces telomere dysfunction and inhibits non-canonical telomerase activity in esophageal carcinomas |
| Q55443450 | Telomere Maintenance Mechanisms in Cancer. |
| Q49922510 | Temozolomide-associated Hypermutation in Gliomas |
| Q47840899 | The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. |
| Q90596932 | The Solo Play of TERT Promoter Mutations |
| Q89470187 | The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival |
| Q28387839 | The epidemiology of glioma in adults: a "state of the science" review |
| Q38349169 | The evolving molecular genetics of low-grade glioma |
| Q41542800 | The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas |
| Q38903424 | The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism. |
| Q39074023 | The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children. |
| Q90744618 | Therapeutic Targets in Telomerase and Telomere Biology of Cancers |
| Q26739925 | Transcription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) Gene |
| Q38760235 | Understanding TERT Promoter Mutations: A Common Path to Immortality. |
| Q51612185 | hTERT promoter methylation in meningiomas and central nervous hemangiopericytomas. |
| Q92738426 | miR‑378a‑3p inhibits cellular proliferation and migration in glioblastoma multiforme by targeting tetraspanin 17 |
Search more.